FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Forxiga
approved in China for heart failure
4 February 2021 07:00
GMT
Forxiga approved in China for heart
failure
Forxiga is the first SGLT2 inhibitor approved in China for heart
failure with reduced ejection fraction in adult patients with and
without type-2 diabetes
AstraZeneca's Forxiga (dapagliflozin) has been approved in China
to reduce the risk of cardiovascular (CV) death and hospitalisation
for heart failure (hHF) in adults with heart failure (NYHA class
II-IV) with reduced ejection fraction (HFrEF).
Heart failure (HF) is a life-threatening chronic disease that
prevents the heart from pumping sufficient levels of blood around
the body.1 At
least half of patients with HF have a reduced ejection fraction
(EF),2 which
occurs when the left ventricle muscle is not able to contract
adequately, and therefore expels less oxygen-rich blood into the
body.3-5
The approval by China's National Medical Products Administration
(NMPA) is based on positive results from the landmark DAPA-HF Phase
III trial, published in The
New England Journal of Medicine. The NMPA's Center for Drug Evaluation granted
DAPA-HF priority review in May 2020.
Junbo Ge, Professor, Director and Doctoral advisor in the
Department of Cardiology, Zhongshan Hospital, Fudan University,
China, and investigator in the DAPA-HF Phase III trial, said: "The
mortality rate of cardiovascular disease far exceeds that of cancer
and other diseases, making it a leading cause of death in China.
The DAPA-HF trial enrolled Chinese patients from 30 sites. Its
results and today's approval will support a new standard of care
for the millions of people in China living with heart
failure."
Mene Pangalos, Executive Vice President, BioPharmaceuticals
R&D, said: "There is no known cure for chronic heart failure
except for heart transplantation, which is why there is an urgent
need for new treatment options that can improve symptoms and help
patients live longer. This approval marks another important step
forward in our ambition to improve outcomes for millions of people
worldwide living with this life-threatening disease."
The DAPA-HF Phase III trial demonstrated
that Forxiga, in addition to the standard of care consisting
of an angiotensin-converting enzyme inhibitor (ACEi) or an
angiotensin receptor blocker (ARB), reduced the risk of the
composite of CV death or worsening of HF events, including hHF
versus placebo by 26%, and both components of the primary composite
endpoint contributed benefit to the overall
effect.6 Forxiga is
the first sodium-glucose co-transporter 2 (SGLT2) inhibitor to have
shown this benefit. In the DAPA-HF Phase III trial, the safety
profile of Forxiga was consistent with the well-established
safety profile of the medicine. During the trial, one CV death or
hHF or an urgent HF visit resulting in intravenous therapy
associated with HF could be avoided for every 21 patients treated
with Forxiga.6
Forxiga (known
as Farxiga in the US) is approved in
the US, Europe, Japan and
several other countries around the world for the treatment of adult
patients with HFrEF.
Forxiga is advancing
knowledge of cardiorenal protection as science continues to
identify the underlying links between the heart, kidneys and
pancreas. DAPA-HF is part of DapaCare, a robust clinical
trial programme to assess the potential CV and renal benefits
of Forxiga. The programme has also explored the treatment of
patients with chronic kidney disease (CKD) in the DAPA-CKD Phase
III trial, with the full results announced
in August
2020 demonstrating
that Forxiga met
all primary and secondary endpoints, including all-cause mortality.
Additionally, Forxiga is
currently being tested in HF patients with preserved ejection
fraction (HFpEF) in the DELIVER Phase III trial, with data readout
anticipated in the second half of 2021, and in patients
without type-2 diabetes (T2D) following an acute myocardial
infarction (MI) or heart attack in the DAPA-MI Phase III trial - a
first of its kind, indication-seeking registry-based randomised
controlled trial.
Heart failure
Heart failure affects approximately 64 million people worldwide (at
least half of whom have a reduced ejection
fraction),2,7 including
approximately 15 million in the EU, six million in the
US,8,9 and
seven million treated adults in China.10 It
is a chronic disease where half of patients will die within five
years of diagnosis.11 There
are two main categories of HF related to EF, a measurement of the
percentage of blood leaving the heart each time it contracts: HFrEF
and HFpEF.3 HFrEF
occurs when the left ventricle muscle is not able to contract
adequately and therefore, expels less oxygen-rich blood in to the
body.4,5 HF
remains as fatal as some of the most common cancers in both men
(prostate and bladder cancers) and women (breast
cancer).12 Chronic
HF is the leading cause of hospitalisation for those over the age
of 65 and represents a significant clinical and economic
burden.13
DAPA-HF
DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart
Failure) is an international, multi-centre, parallel-group,
randomised, double-blinded Phase III trial in 4,744 patients with
heart failure and reduced ejection fraction (LVEF ≤ 40%),
with and without T2D, designed to evaluate the effect
of Forxiga 10mg,
compared with placebo, given once daily in addition to standard of
care consisting of an ACEi or an ARB. The primary composite
endpoint was time to the first occurrence of a worsening heart
failure event (hospitalisation or equivalent event; i.e. an urgent
heart failure visit), or cardiovascular death. The median duration
of follow-up was 18.2 months.
Forxiga
Forxiga (dapagliflozin) is
a first-in-class, oral, once-daily SGLT2
inhibitor.
The research for Forxiga is advancing from cardiorenal effects to
prevention and organ protection as science continues to identify
the underlying links between the heart, kidneys and pancreas.
Damage to one of these organs can cause the other organs to fail -
contributing to leading causes of death worldwide, including T2D,
HF and CKD.
For nearly a decade Forxiga has been an effective monotherapy and part
of combination therapy as an adjunct to diet and exercise to
improve glycaemic control in adults with T2D. Following results
from the landmark DECLARE-TIMI 58 Phase III CV outcomes trial, it
is approved in adults with T2D to reduce the risk of hHF or CV
death when added to standard of care. Forxiga is also the first SGLT2
inhibitor approved for the
treatment of HFrEF in adults with and without
T2D.
In August 2020, results from the
DAPA-CKD Phase III trial demonstrated that Forxiga achieved unprecedented reduction in the
composite risk of kidney failure and CV or renal death in patients
with CKD versus placebo. It is now the first SGLT2 inhibitor shown
to significantly prolong survival in a renal outcomes trial for
this patient population and provide organ
protection. Forxiga is not indicated for the treatment of
CKD.
DapaCare is a robust programme of clinical trials to evaluate the
potential CV, renal and organ protection benefits
of Forxiga. It includes more than 35 completed and ongoing
Phase IIb/III trials in more than 35,000 patients, as well as more
than 2.5 million patient-years' experience. It is currently being
assessed in patients with HF with preserved ejection fraction in
the DELIVER Phase III trial. Forxiga is also being tested in patients without T2D
following an acute MI or heart attack in the DAPA-MI Phase III
trial - a first of its kind, indication-seeking registry-based
randomised controlled trial.
AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM) together forms one of
AstraZeneca's three therapy areas and is a key growth driver for
the Company. By following the science to understand more clearly
the underlying links between the heart, kidneys and pancreas,
AstraZeneca is investing in a portfolio of medicines to protect
organs and improve outcomes by slowing disease progression,
reducing risks and tackling comorbidities. The Company's ambition
is to modify or halt the natural course of CVRM diseases and
potentially regenerate organs and restore function, by continuing
to deliver transformative science that improves treatment practices
and cardiovascular health for millions of patients
worldwide.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. Mayo Clinic. Heart
Failure; 29 May 2020 [cited 5 January 2021]. Available from:
URL: https://www.mayoclinic.org/diseases-conditions/heart-failure/symptoms-causes/syc-20373142.
2. Travessa AMR, Menezes
Falcão LF de. Treatment of Heart Failure With Reduced
Ejection Fraction-Recent Developments. Am J Ther 2016; 23(2):e531-49.
3. American Heart
Association. Ejection Fraction Heart Failure Measurement; 2017
[cited 2 Nov 2020]. Available from: URL: https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failure-measurement.
4. Ponikowski P et al. 2016 ESC
Guidelines for the Diagnosis and Treatment of Acute and Chronic
Heart Failure: The Task Force for the Diagnosis and Treatment of
Acute and Chronic Heart Failure of the European Society of
Cardiology (ESC) Developed with the Special Contribution of the
Heart Failure Association (HFA) of the
ESC. Eur
Heart J 2016;
37(27):2129-200.
5.
National Guideline Centre (UK). Chronic Heart Failure in Adults:
Diagnosis and Management. London: National Institute for Health and
Care Excellence (UK); 2018 Sep. (NICE Guideline, No. 106.) 13,
Glossary.
6. McMurray JJV et al. Dapagliflozin
in Patients with Heart Failure and Reduced Ejection
Fraction. N Engl J
Med 2019;
381(21):1995-2008.
7. Vos T et al. Global, Regional, and
National Incidence, Prevalence, and Years Lived with Disability for
328 Diseases and Injuries for 195 Countries, 1990-2016: A
Systematic Analysis for the Global Burden of Disease Study
2016. Lancet 2017;
390(10100):1211-59.
8. Dickstein K et al. ESC Guidelines
for the Diagnosis and Treatment of Acute and Chronic Heart Failure
2008: the Task Force for the Diagnosis and Treatment of Acute and
Chronic Heart Failure 2008 of the European Society of Cardiology.
Developed in Collaboration with the Heart Failure Association of
the ESC (HFA) and Endorsed by the European Society of Intensive
Care Medicine (ESICM). Eur Heart J 2008; 29:2388-442.
9. Centers for
Disease Control and Prevention. Heart Disease: Heart Failure. 8
September 2020. https://www.cdc.gov/heartdisease/heart_failure.htm#:~:text=Facts%20About%20Heart%20Failure%20in,estimated%20%2430.7%20billion%20in%202012.
10.
AstraZeneca. Data on File. February 2020.
11. Mozaffarian D et al. Heart Disease and
Stroke Statistics-2016 Update: A Report From the American Heart
Association. Circulation 2016; 133(4):e38-360.
12. Mamas MA et al. Do Patients Have Worse
Outcomes in Heart Failure than in Cancer? A Primary Care-Based
Cohort Study with 10-year Follow-up in
Scotland. Eur J Heart
Fail 2017;
19(9):1095-104.
13. Azad N, Lemay G. Management of Chronic
Heart Failure in the Older Population. J Geriatr
Cardiol 2014;
11(4):329-37.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
04 February
2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|